Acura Pharmaceuticals, Inc. (ACUR)

USD 0.0

(0.0%)

Market Cap (In USD)

211.2 Thousand

Revenue (In USD)

-

Net Income (In USD)

-

Avg. Volume

62.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-4-0.7532
PE
-
EPS
-
Beta Value
49.968
ISIN
US00509L8028
CUSIP
00509L802
CIK
786947
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Robert B. Jones
Employee Count
-
Website
https://www.acurapharm.com
Ipo Date
1986-03-28
Details
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.